# Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia

> **NCT00338299** · PHASE2 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 51 (actual)

## Conditions studied

- Anemia
- Chemotherapy

## Interventions

- **DRUG:** Epoetin alfa

## Key facts

- **NCT ID:** NCT00338299
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** —
- **Final completion:** 2004-04
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2011-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00338299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00338299, "Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00338299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*